Pioneering gut mucosal-immune science to prevent and treat gastrointestinal diseases

Pioneering gut mucosal-immune science to prevent and treat gastrointestinal diseases

Our Solutions

GI Discovery Platform

Measures metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery, development, and clinical decision support.

3 Leading Use Cases

CS Therapeutic Platform

Mucosal Immune Modulator (MIM) therapeutic that restores and protects the mucosal-immune barrier in the gastrointestinal tract.

7 Indications
Lead Asset: CS-0003

Our focus is on preventing and treating GI disease with novel therapeutics & GI Discovery platform.

I will prevent disease whenever I can, for prevention is preferable to cure.

– Physicians’ Hippocratic Oath

Dr. Chang on gray background with teal border

32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics

January 8, 2026

32 Biosciences Set to Attend the 2026 JPM Healthcare Conference

December 31, 2025

32 Biosciences Joins Featured Startups in the Midwest Biotech Startup Showcase

December 31, 2025